KPV: Research, Mechanism & Current Evidence

What is KPV?

KPV is the last three amino acids — lysine, proline and valine — of alpha-melanocyte-stimulating hormone, a natural signalling molecule. Researchers isolated this fragment because it appears to keep the anti-inflammatory activity of the parent hormone without the pigmentation effects.

That separation is the reason KPV is studied separately from melanotan compounds, which act on the same parent hormone's pigmentation pathway.

What is KPV researched for?

Inflammatory bowel disease models are the most developed area, particularly colitis in mice.

Other work covers skin inflammation, wound healing and antimicrobial activity against bacteria and fungi.

• Reduces TNF-α and IL-6 through NF-κB pathway inhibition.
• May help balance overactive immune responses in autoimmune conditions.
• Potential benefits for inflammatory arthritis through cytokine reduction.
• Demonstrated benefit in Crohn's disease and ulcerative colitis models.
• Helps restore intestinal barrier function.
• Selective antimicrobial activity preserves beneficial gut bacteria.
• Topical KPV reduced psoriatic markers by 60% and improved skin barrier function.
• Reduces inflammatory skin conditions without systemic effects.

How does KPV work?

Inflammation is driven in part by a signalling switch inside cells called NF-κB. KPV has been reported to reduce activation of that switch, lowering the production of inflammatory messengers.

In gut research, a notable finding is that KPV appears to be taken up directly by intestinal cells through peptide transporters, which is why oral and localised delivery are studied rather than injection alone.

What does the research show?

The strongest data comes from rodent colitis models, where KPV reduced markers of inflammation and tissue damage at very low doses. Cell-culture work supports the proposed mechanism.

Antimicrobial activity has been demonstrated in laboratory conditions against several organisms.

Limitations of the current evidence

There are no published controlled human trials of KPV in any indication.

Results in mouse colitis models have historically translated poorly into human inflammatory bowel disease.

References

1. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides

   Getting SJ, Schiöth HB, Perretti M · The Journal of pharmacology and experimental therapeutics · 2003

   Established that KPV exerts anti-inflammatory effects distinct from core MSH peptides, likely through inhibition of IL-1β functions rather than melanocortin receptor signaling.

   PMID 12750433

2. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation

   Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. · Gastroenterology · 2008

   KPV is transported into cells via PepT1, where nanomolar concentrations inhibit NF-κB and MAP kinase signaling pathways. Oral KPV reduced DSS- and TNBS-induced colitis in mice.

   Animal study · PMID 18061177

3. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease

   Kannengiesser K, Maaser C, Heidemann J, et al. · Inflammatory bowel diseases · 2008

   KPV showed significant anti-inflammatory effects in DSS colitis and CD45RBhi transfer colitis models, reducing weight loss, histological damage, and MPO activity. Effects partially independent of MC1R signaling.

   Animal study · PMID 18092346

4. Critical Role of PepT1 in Promoting Colitis-Associated Cancer and Therapeutic Benefits of KPV

   Viennois, E., et al. · Cellular and Molecular Gastroenterology and Hepatology · 2016

   PepT1 is highly expressed in human colorectal tumors. PepT1-transported KPV prevented colitis-associated carcinogenesis in wild-type mice, with no effect in PepT1-knockout mice, confirming PepT1-dependent therapeutic mechanism.

   Animal study

5. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis

   Xiao B, Xu Z, Viennois E, et al. · Molecular therapy : the journal of the American Society of Gene Therapy · 2017

   HA-functionalized KPV nanoparticles (~272.3 nm) successfully targeted colonic epithelial cells and macrophages, exerting combined mucosal healing and anti-inflammatory effects superior to free KPV in a UC mouse model.

   Animal study · PMID 28143741

6. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model

   Viennois E, Ingersoll SA, Ayyadurai S, et al. · Cellular and molecular gastroenterology and hepatology · 2016

   Animal study · PMID 27458604

Common questions